Literature DB >> 31423536

Severe dengue in travellers: pathogenesis, risk and clinical management.

Scott Halstead1, Annelies Wilder-Smith2,3.   

Abstract

RATIONALE FOR REVIEW: Dengue is a frequent cause of febrile illness among travellers and has overtaken malaria as the leading cause of febrile illness for those traveling to Southeast Asia. The purpose is to review the risk of dengue and severe dengue in travellers with a particular focus on the pathogenesis and clinical management of severe dengue. RISK, PATHOGENESIS AND CLINICAL MANAGEMENT: The risk of travel-acquired dengue depends on destination, season and duration of travel and activities during travel. Seroconversion rates reported in travellers, therefore, vary between <1% and >20%. The most common life-threatening clinical response to dengue infection is the dengue vascular permeability syndrome, epidemiologically linked to secondary infection, but can also occur in primary infection. Tertiary and quaternary infections are usually associated with mild or no disease. Antibody-dependent enhancement, viral factors, age, host factors and clinical experience of the managing physician modulate the risk of progressing to severe dengue. The relative risk of severe dengue in secondary versus primary infection ranges from 2 to 7. The absolute risk of severe dengue in children in highly endemic areas is ~0.1% per year for primary infections and 0.4% for secondary infections. About 2-4% of secondary infections lead to severe dengue. Severe dengue and death are both relatively rare in general travellers but more frequently in those visiting friends and relatives. Clinical management of severe dengue depends on judicious use of fluid rehydration.
CONCLUSIONS: Although dengue is a frequent cause of travel illness, severe dengue and deaths are rare. Nevertheless, dengue infections can interrupt travel and lead to evacuation and major out-of-pocket costs. Dengue is more frequent than many other travel-related vaccine preventable diseases, such as hepatitis A, hepatitis B, rabies, Japanese encephalitis and yellow fever, indicating a need for a dengue vaccine for travellers. © International Society of Travel Medicine 2019. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Aedes; Antibody-dependent enhancement; CYD-TDV; capillary leakage; dengue haemorrhagic fever; dengue vaccines; risk assessment

Mesh:

Year:  2019        PMID: 31423536     DOI: 10.1093/jtm/taz062

Source DB:  PubMed          Journal:  J Travel Med        ISSN: 1195-1982            Impact factor:   8.490


  28 in total

Review 1.  Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003/TV005.

Authors:  Anna P Durbin
Journal:  Curr Opin Virol       Date:  2020-10-23       Impact factor: 7.090

2.  Evaluating Dengue Virus Pathogenesis in Mice and Humans by Histological and Immunohistochemistry Approaches.

Authors:  Natália G Salomão; Kíssila Rabelo; Marciano V Paes
Journal:  Methods Mol Biol       Date:  2022

Review 3.  Vaccines and Senior Travellers.

Authors:  Fiona Ecarnot; Stefania Maggi; Jean-Pierre Michel; Nicola Veronese; Andrea Rossanese
Journal:  Front Aging       Date:  2021-07-09

Review 4.  Protective and enhancing interactions among dengue viruses 1-4 and Zika virus.

Authors:  Leah C Katzelnick; Sandra Bos; Eva Harris
Journal:  Curr Opin Virol       Date:  2020-09-24       Impact factor: 7.090

5.  Zika among international travellers presenting to GeoSentinel sites, 2012-2019: implications for clinical practice.

Authors:  Kristina M Angelo; Rhett J Stoney; Gaelle Brun-Cottan; Karin Leder; Martin P Grobusch; Natasha Hochberg; Susan Kuhn; Emmanuel Bottieau; Patricia Schlagenhauf; Lin Chen; Noreen A Hynes; Cecilia Perret Perez; Frank P Mockenhaupt; Israel Molina; Clara Crespillo-Andújar; Denis Malvy; Eric Caumes; Pierre Plourde; Marc Shaw; Anne E McCarthy; Nancy Piper-Jenks; Bradley A Connor; Davidson H Hamer; Annelies Wilder-Smith
Journal:  J Travel Med       Date:  2020-07-14       Impact factor: 8.490

6.  Target Identification Using Homopharma and Network-Based Methods for Predicting Compounds Against Dengue Virus-Infected Cells.

Authors:  Kowit Hengphasatporn; Kitiporn Plaimas; Apichat Suratanee; Peemapat Wongsriphisant; Jinn-Moon Yang; Yasuteru Shigeta; Warinthorn Chavasiri; Siwaporn Boonyasuppayakorn; Thanyada Rungrotmongkol
Journal:  Molecules       Date:  2020-04-18       Impact factor: 4.411

7.  Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City.

Authors:  Shibadas Biswal; Jorge Fernando Mendez Galvan; Mercedes Macias Parra; Juan-Francisco Galan-Herrera; Monica Belisa Carrascal Rodriguez; Esteban Patricio Rodriguez Bueno; Manja Brose; Martina Rauscher; Inge LeFevre; Derek Wallace; Astrid Borkowski
Journal:  Rev Panam Salud Publica       Date:  2021-06-11

8.  Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Quadrivalent Human Papillomavirus Vaccine in Boys and Girls 9-13 Years of Age in Malaysia: A Phase IIIb, Randomized, Open-label Study.

Authors:  Jamiyah Hassan; Teck-Hock Toh; Selva Kumar Sivapunniam; Ruziaton Hasim; Nor Faizah Ghazali; Sofiah Sulaiman; Mia Tuang Koh; Stephanie Meyer; Myew-Ling Toh; Celine Zocchetti; Claire Vigne; Cesar Mascareñas
Journal:  Pediatr Infect Dis J       Date:  2021-08-01       Impact factor: 2.129

9.  Risk predictors of progression to severe disease during the febrile phase of dengue: a systematic review and meta-analysis.

Authors:  Sorawat Sangkaew; Damien Ming; Adhiratha Boonyasiri; Kate Honeyford; Siripen Kalayanarooj; Sophie Yacoub; Ilaria Dorigatti; Alison Holmes
Journal:  Lancet Infect Dis       Date:  2021-02-25       Impact factor: 25.071

Review 10.  Dengue vaccine development: status and future.

Authors:  Annelies Wilder-Smith
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2020-01       Impact factor: 1.513

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.